The next generation of targeted cancer therapies
About Tavros | A precision oncology company
Tavros Therapeutics is discovering and developing first-in-class, targeted cancer therapies. We are a science-first company and believe the future of cancer therapy lies in identifying how to best position drugs in the clinic through a deep understanding of drug biology. We use cutting-edge functional genomics technologies to uncover unique vulnerabilities within the tumor to discover context-specific cancer drugs, targets, and approaches. We are driven to make an impact on cancer by developing the next generation of targeted cancer therapies to dramatically improve outcomes for cancer patients.
Small molecule pipeline
Tavros is pursuing first-in-class small molecule inhibitors of undisclosed drug targets.
Drug discovery programs
We are using our drug-first functional genomics screening approach to pursue strategic, underserved areas in cancer biology.
Collaborations and partnering of select Tavros owned IP/drugs. In 2020 Tavros signed a partnership with Zentalis Pharmaceuticals.